These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 25238407

  • 1. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
    Zhao S, Jiang T, Tang H, Cui F, Liu C, Guo F, Lu H, Xue Y, Jiang W, Peng Z, Yan D.
    J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
    [Abstract] [Full Text] [Related]

  • 2. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
    Öhrling K, Karlberg M, Edler D, Hallström M, Ragnhammar P.
    Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
    [Abstract] [Full Text] [Related]

  • 3. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
    Giráldez MD, Lozano JJ, Cuatrecasas M, Alonso-Espinaco V, Maurel J, Mármol M, Hörndler C, Ortego J, Alonso V, Escudero P, Ramírez G, Petry C, Lasalvia L, Bohmann K, Wirtz R, Mira A, Castells A.
    Int J Cancer; 2013 Mar 01; 132(5):1090-7. PubMed ID: 22833293
    [Abstract] [Full Text] [Related]

  • 4. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, Zhao HW, Chen W, He YL, Wang HY, Xie D, Luo JH.
    Lancet Oncol; 2013 Dec 01; 14(13):1295-306. PubMed ID: 24239208
    [Abstract] [Full Text] [Related]

  • 5. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S, Tibiche C, Zou J, Zaman N, Trifiro M, O'Connor-McCourt M, Wang E.
    JAMA Oncol; 2016 Jan 01; 2(1):37-45. PubMed ID: 26502222
    [Abstract] [Full Text] [Related]

  • 6. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM.
    J Clin Oncol; 2004 May 15; 22(10):1797-806. PubMed ID: 15067028
    [Abstract] [Full Text] [Related]

  • 7. High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer.
    Park JS, Chon HJ, Jeung HC, Shin SJ, Rha SY, Ahn JB, Lee KY, Kim NK, Chung HC.
    J Cancer Res Clin Oncol; 2016 Sep 15; 142(9):2051-9. PubMed ID: 27447697
    [Abstract] [Full Text] [Related]

  • 8. Nuclear Maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer.
    Dietmaier W, Bettstetter M, Wild PJ, Woenckhaus M, Rümmele P, Hartmann A, Dechant S, Blaszyk H, Pauer A, Klinkhammer-Schalke M, Hofstädter F.
    Int J Cancer; 2006 May 01; 118(9):2247-54. PubMed ID: 16331619
    [Abstract] [Full Text] [Related]

  • 9. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
    Lou YT, Chen CW, Fan YC, Chang WC, Lu CY, Wu IC, Hsu WH, Huang CW, Wang JY.
    PLoS One; 2014 May 01; 10(4):e0123973. PubMed ID: 25919688
    [Abstract] [Full Text] [Related]

  • 10. Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
    Kornmann M, Staib L, Wiegel T, Kron M, Henne-Bruns D, Link KH, Formentini A, Study Group Oncology of Gastrointestinal Tumors (FOGT).
    Clin Colorectal Cancer; 2013 Mar 01; 12(1):54-61. PubMed ID: 23107590
    [Abstract] [Full Text] [Related]

  • 11. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
    O'Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, André T, Haller DG, Sargent DJ.
    J Clin Oncol; 2008 May 10; 26(14):2336-41. PubMed ID: 18467725
    [Abstract] [Full Text] [Related]

  • 12. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, Hollema H, Boezen HM, Mulder NH, Plukker JT, de Jong S, Kleibeuker JH, Koornstra JJ.
    J Clin Oncol; 2006 Nov 01; 24(31):4998-5004. PubMed ID: 17075118
    [Abstract] [Full Text] [Related]

  • 13. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
    Yun HR, Kim HC, Yun SH, Lee WY.
    Hepatogastroenterology; 2012 Nov 01; 59(120):2466-71. PubMed ID: 23169179
    [Abstract] [Full Text] [Related]

  • 14. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C.
    Oncology; 2006 Nov 01; 70(5):366-77. PubMed ID: 17179731
    [Abstract] [Full Text] [Related]

  • 15. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
    Hong KD, Lee SI, Moon HY.
    Hepatogastroenterology; 2012 Nov 01; 59(113):104-7. PubMed ID: 22251527
    [Abstract] [Full Text] [Related]

  • 16. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
    Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger GG, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J, Austrian Breast and Colorectal Cancer Study Group.
    Br J Cancer; 2007 Oct 22; 97(8):1021-7. PubMed ID: 17895886
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
    Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N, Wieand HS.
    J Clin Oncol; 2003 Jan 15; 21(2):241-50. PubMed ID: 12525515
    [Abstract] [Full Text] [Related]

  • 18. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS.
    Cancer Chemother Pharmacol; 2010 Sep 15; 66(4):659-67. PubMed ID: 20033812
    [Abstract] [Full Text] [Related]

  • 19. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
    Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM.
    Oncologist; 2017 Jan 15; 22(1):107-114. PubMed ID: 27821793
    [Abstract] [Full Text] [Related]

  • 20. Prognostic relevance of Src activation in stage II-III colon cancer.
    Martínez-Pérez J, Lopez-Calderero I, Saez C, Benavent M, Limon ML, Gonzalez-Exposito R, Soldevilla B, Riesco-Martínez MC, Salamanca J, Carnero A, Garcia-Carbonero R.
    Hum Pathol; 2017 Sep 15; 67():119-125. PubMed ID: 28601656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.